The Federal Circuit ruling in Acorda v Mylan and AstraZeneca v Mylan gives branded pharmaceutical companies more flexibility in their choice of where to file suit against generics
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck